/
VRAX
$4.12-$2.24 (-35.25%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.1M
1M shares
52-week range
$2.50 – $28.50
6% from low
Exchange
NASDAQ
CS
Borrow rate
103.34%
Hard to borrow
Change$-4545.88
Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
www.viraxbiolabs.com- Employees
- 26
- IPO / List date
- Jul 21, 2022
Held by traders on TradeandTell
No one on the platform currently holds VRAX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in VRAX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-26 | 1-for-25reverse |
| 2023-12-18 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded VRAX yet.
